Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Cannabis Use Disorder
NCT07523633Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in cannabis use disorder (CUD). Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT07523633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523633.